Kitch Wilson
Private Equity Investor chez Pioneer Fund/NY/
Profil
Kitch Wilson is a professional who has worked as an Advisor at Bell Biosystems, Inc. from 2011 to 2014.
Currently, he is a Venture Partner at Pioneer Fund since 2023.
Mr. Wilson has a graduate degree from Stanford University and Duke University School of Medicine.
Postes actifs de Kitch Wilson
| Sociétés | Poste | Début |
|---|---|---|
Pioneer Fund/NY/
 Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01/10/2023 |
Anciens postes connus de Kitch Wilson
| Sociétés | Poste | Fin |
|---|---|---|
Bell Biosystems, Inc.
 Bell Biosystems, Inc. BiotechnologyHealth Technology Bell Biosystems, Inc. operates as a synthetic biology company. It develops Magnelle, a synthetic organelle that produces magnetic nanoparticles from intracellular iron, as well as enables to track, control, and destroy transplanted cells in vivo. The firm's product is used in regenerative medicine, oncology, and other cell-based fields. The company was founded by Caleb B. Bell III and Daniel Bell in June 2009 and is headquartered in San Francisco, CA. | Consultant / Advisor | 01/04/2014 |
Formation de Kitch Wilson
| Stanford University | Graduate Degree |
| Duke University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Pioneer Fund/NY/
Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Finance |
Bell Biosystems, Inc.
Bell Biosystems, Inc. BiotechnologyHealth Technology Bell Biosystems, Inc. operates as a synthetic biology company. It develops Magnelle, a synthetic organelle that produces magnetic nanoparticles from intracellular iron, as well as enables to track, control, and destroy transplanted cells in vivo. The firm's product is used in regenerative medicine, oncology, and other cell-based fields. The company was founded by Caleb B. Bell III and Daniel Bell in June 2009 and is headquartered in San Francisco, CA. | Health Technology |
